PANTHERx Selected by UCB as Exclusive Specialty Pharmacy for ZILBRYSQ

UCB, a global biopharmaceutical company, announced that ZILBRYSQ^® (zilucoplan) is now available in the U.S. for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

ZILBRYSQ was approved by the U.S. Food and Drug Administration (FDA) on October 17, 2023. ZILBRYSQ is available by prescription as a ready-to-use pre-filled syringe that is a once-daily administration.

Zilbrysq is available through the specialty pharmacy PANTHERx Rare Pharmacy and through a Risk Evaluation and Mitigation Strategy (REMS) program because of the risk of serious meningococcal infections.

PANTHERx^® Rare was selected in August 2023 by UCB as a limited distribution partner to provide RYSTIGGO^® (rozanolixizumab-noli), the first and only FDA-approved targeted treatment for both anti- acetylcholine receptor (AChR)  anti- muscle-specific tyrosine kinase (MuSK) antibody positive adult patients with generalized myasthenia gravis (gMG).

PANTHERx Rare is the leader in rare disease pharmacy in the United States, transforming the lives of individuals with rare and devastating conditions by delivering medicine breakthroughs, clinical excellence, and access to vital care solutions.

PANTHERx is focused on medications that have Orphan designation by the FDA and where the manufacturer chooses an exclusive or highly limited specialty pharmacy distribution strategy.